e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
American Battery Technology Co.
AppTech Payments Corp. - Common stock
CleanSpark, Inc. - Common Stock
Daseke, Inc. - Warrant
Euro Manganese Inc
First Hydrogen Corp
Mithril Silver & Gold Ltd
PTL LTD - Class A Ordinary Shares
Paramount Group, Inc. Common Stock
Pharmchem Inc
Pmv Consumer Acquisition Corp
Salazar Resources Ltd Ord
State Street SPDR Portfolio Long Term Corporate Bond ETF
TFS Financial Corporation - Common Stock
Vanguard FTSE Dev All Cap Na Idx
Voya Emerging Markets High Income Dividend Equity Fund Common Shares
Xylo Technologies Ltd. - American Depositary Shares
byNordic Acquisition Corporation - Class A Common Stock
iShares U.S. Telecommunications ETF
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Panbela Therapeutics, Inc. - Common Stock
(OP:
PBLA
)
0.0010
UNCHANGED
Delayed Quote
Updated: 2:26 PM EDT, Oct 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Panbela Therapeutics, Inc. - Common Stock
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
October 31, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
September 24, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
↗
August 14, 2024
PBLA stock results show that Panbela Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 24, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 10, 2024
Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin American
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert